uniQure N.V. - Special Call Transcript
Good morning, and thank you for joining us. This morning, uniQure announced that its hemophilia B gene therapy program has been placed on clinical hold by the U.S. Food and Drug Administration, pending review of a serious adverse event. This SAE is associated with the preliminary diagnosis of a form of liver cancer in one patient in the HOPE-B clinical trial being studied in adult patients with severe and moderately severe hemophilia B.
Joining me for this investor event and webcast are Mat Kapusta, our Chief Executive Officer; Dr. Ricardo Dolmetsch, our President of Research and Development; Eileen Sawyer, our Vice President of Global Medical Affairs; Dr. David Cooper, our Vice President of Clinical Development; Dr. Steven Pipe, Professor of Pediatrics and Pathology and the Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program at the University of Michigan and the Principal Investigator of the HOPE-B pivotal trial of EtranaDez; and Dr. Graham Foster, Professor of Hepatology at Queen Mary University in London
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |